2026 UPDATE - Current Status of the ADHD Stimulant Shortage

There have been several important developments since I wrote the original post (https://www.drjonslaughter.com/post/understanding-adhd-the-stimulant-shortage-and-its-impact-on-individuals-and-society) regarding the National stimulant shortage.

Current Status of the ADHD Stimulant Shortage (2026)

Although the FDA declared the shortage of some amphetamine products resolved in late 2024, the reality for patients has remained far more complicated. The shortage has evolved rather than ended.

Current issues include:

• Regional shortages continue. Many pharmacies still experience intermittent shortages of Adderall, generic amphetamine salts, Vyvanse (particularly generic lisdexamfetamine), and certain methylphenidate formulations.

• Generic substitutions remain inconsistent. Insurance companies often require generic medications, but many generic manufacturers continue to experience production variability.

• Patients frequently must contact multiple pharmacies before finding medication in stock, creating significant delays in treatment.

• Independent pharmacies generally report greater difficulty obtaining stimulant medications than large chain pharmacies.

• DEA manufacturing quotas, although adjusted upward several times, continue to be criticized by physicians and patient advocacy groups as not adequately reflecting actual patient demand.

• Manufacturers have reported that available quota often exceeds what they are able to manufacture because of labor shortages, raw material issues, and manufacturing capacity constraints.

Actions Taken by Authorities

Several federal agencies have attempted to address the shortage.

DEA

• Increased annual production quotas for amphetamine and methylphenidate products.

• Began allowing more flexibility in transferring unused manufacturing quota between manufacturers.

• Has acknowledged that production quotas alone are not the sole cause of shortages.

FDA

• Continues to maintain a public Drug Shortages Database.

• Meets regularly with manufacturers to identify bottlenecks.

• Has encouraged manufacturers to increase production where possible.

• Has improved communication regarding expected release dates of medications.

HHS and Congress

• Several congressional hearings have examined the causes of the shortage.

• Medical organizations including the American Academy of Pediatrics, American Psychiatric Association, and CHADD have advocated for improved transparency regarding production limits and supply chain issues.

• Policymakers continue discussing reforms to better match DEA quotas with real-world prescribing trends.

Unfortunately, despite these efforts, many psychiatrists including myself, continue to report that obtaining stimulant medications remains one of the most common frustrations expressed by patients. This is a profound challenge leading individuals to be unable to obtain the medication they need to treat their medical condition. In addition, the many distortions about this class of medication in our society leads people to be judged by others to include pharmacists as they try to obtain their medication adding feelings of guilt and shame to the anxiety and powerlessness they experience as their symptoms interfere with their functioning in their personal and professional lives.

Options to Address Your Symptoms

Due to this ongoing challenge it is more important than ever to consider other interventions such as mindfulness, adaptogens and other molecules proven to improve attention and concentration, and CBT for ADHD to address symptoms. Learn more about these approaches here: https://www.drjonslaughter.com/post/evidence-based-adhd-treatment .

If you are interested in exploring these options please contact me to set up the free 15 minute phone consultation I offer to discuss if starting in care could be of benefit to you (https://www.drjonslaughter.com/contact-8).